Additionally, there has been a 45% increase in drugs received from clinics and a 35% increase from mail-order pharmacies over the same period. Cardiovascular therapies retained 22.50% of 2024 revenue on the back of entrenched prescription volumes for antihypertensives, statins, and antithrombotics. Long-cycle consumption fosters predictable demand curves, enabling manufacturers to fine-tune capacity allocation. Branded reference price erosion remains gradual, allowing disciplined generic price management that stabilizes gross margins despite competitive density.
For instance, as per the Revised National Tuberculosis Control Programme Report, ~4.4 lakh patients died due to tuberculosis in India in 2018, i.e., 29% of the total 1.5 million deaths caused by the disease across the world. Thus, the rising incidence of chronic diseases and infectious diseases bolsters the demand for drugs, which would continue to drive the US pharmaceutical market growth in the future. One of the critical elements driving the global market growth is the increasing launches of the generic equivalents of several key drugs in strong markets such as the U.S. The increasing adoption of these generic equivalents is especially due to the fact that these generics are often as efficient as their original counterparts and can often be adopted by patients at a fraction of the costs. Patients without access to expensive prescription products due to financial hurdles can often adopt these drugs and experience better clinical outcomes.
Key Highlights
Hospital pharmacies were the top distribution channel, playing a key role in delivering respiratory medications to patients. The global generic drug market is a fiercely competitive arena dominated by a handful of multinational titans, a dynamic cohort of specialized players, and a vast number of smaller regional manufacturers. Success in this environment requires not only operational excellence and scale but also sophisticated strategic planning, astute portfolio management, and a deep understanding of the intellectual property landscape. The leading companies are not standing still; they are actively reshaping their business models to adapt to the industry’s evolving pressures and opportunities. As a result, wecannot examine the costs borne by patients via copays or coinsurance fordrugs resulting from low competition.
Understanding Key Drivers And Growth Opportunities In The Gastroparesis Drugs Market: Trends And Market Size Insights
- Such high investments in R&D activities are driving the growth of the US pharmaceutical market share at present and also in future years.
- Pharmaceutical companies focus on expanding their presence in the U.S. through strategic geographic and demographic targeting.
- The availability of various OTC formulations such as eye drops, gel, and ointments allows consumers to manage minor ocular issues without prescriptions.
- Liquid forms, such as eye drops and solutions, allow for direct drug delivery to the eye, ensuring quick relief and high patient compliance.
- Hospitals increasingly consolidate purchasing consortia to extract further discounts, while voluntary influx of low-cost players from India intensifies competition.
Participants at Fusion 2023 heard that COVID-19-related deaths continue to fall, along with incidence of RSV, cough, colds, and influenza. Deaths from COVID-19 have diminished to close to levels very early in the pandemic, an indication that at least for the present, this is becoming less of a threat. In line with this trend, COVID-19 vaccine uptake continues to diminish, from around 6% of prescriptions in 2021, to 2.5% in 2022, and less than 1% in 2023. Significant spikes were seen in both RSV and norovirus during the latest U.S. cough, cold and flu season, with RSV incidence increasing sharply in the fall of 2022 and continuing into early 2023.
US Pharmaceutical Market Outlook And Strategic Insights By 2030
These products, which are more difficult and costly to develop, create higher barriers to entry, offering a refuge from the hyper-competition of simple oral solids and promising more sustainable profitability. Figure 6 breaksdown the level of competition by total revenue and total molecules in2022 among the highest priced, small molecule drugs (we did not examinebiological products, since there was no competition). We observed thatthe 89 percent of small molecule drugs with only one manufactureraccounted for 86 percent of revenues.
Global Pharmaceutical Market Report Segmentation
Strategic collaborations and investments in R&D continue to drive product development and market competitiveness. The global pharmaceutical market size was estimated at USD 1,645.75 billion in 2024 and is projected to reach USD 2,350.43 billion by 2030, growing at a CAGR of 6.12% from 2025 to 2030. The market is driven by rising chronic disease prevalence, aging populations, and increased healthcare spending.
Generic drugs are typically more affordable than their brand-name counterparts and provide similar therapeutic effects. The availability of off-patent and off-exclusivity drugs contributes to increased accessibility to essential medications and competition in the pharmaceutical market. The US pharmaceutical market accounts for about 45% of the global pharmaceutical market and 22% of global production. The US pharmaceuticals output and sales remained robust in 2022, driven by the global vaccination rollout and suppressed demand for essential and non-essential medical treatments. The US pharmaceutical market has made great strides over the past few decades due to a greater focus on research and development (R&D). Pharma companies spend over 21% of their revenues on R&D, and this sizeable investment is wasted if a medication does not receive regulatory approval.
In An Emergency? Need Treatment?
The increasing incidence of rare diseases is expected to propel the growth of the pharmaceutical drug market going forward. A rare disease refers to a low-prevalence health issue that, in comparison to other common diseases in the population, only affects a tiny number of people. Approximately 80% of these diseases have a recognized genetic basis, with 1 in 17 people expected to be affected by a rare disease at some stage in their life. Therefore, the increasing incidence of rare diseases is driving the growth of the pharmaceutical drug market.
Pharmaceutical Market Size, Trends, Top Companies And Strategies By 2034
The Asia-Pacific prescription drugs market is poised to grow at the fastest CAGR of 7.9% from 2025 to 2032, propelled by rising healthcare investments, population growth, and increasing prevalence of chronic conditions in countries such as China, India, and Japan. Government initiatives to improve healthcare infrastructure and promote access to essential medicines are encouraging pharmaceutical expansion across the region. As APAC becomes a key hub for drug manufacturing and clinical trials, the affordability and accessibility of prescription medications continue to improve across both urban and rural areas.
Distribution Channel Insights
With this blend of convenience, expert support, and budget-friendly options, drug stores and retail pharmacies continue to solidify their position as the linchpin distribution channel in the OTC market. From 2017 through 2022, an increasing share of spending and prescriptionson the highest priced drugs were for biological products, with acorresponding decrease for small molecule drugs. In 2017, biologicalproducts comprised 30 percent of spending and 34 percent ofprescriptions among these highest priced drugs, but by 2022, both ofthese rates had increased to 49 percent. Accordingly, the share of drugspending and utilization of small molecule drugs among the highestpriced drugs dropped from 70 percent to 51 percent and from 66 percentto 51 percent respectively. Additionally, the report highlights other drugs that AdisInsight predicts will be best sellers.
- Hospitals rely on sterile injections for critical care, and five suppliers with established aseptic capacity collectively hold 46% of this subsegment’s generic drugs market share.
- The global generic drug market is characterized by a powerful and sustained growth trajectory, underpinned by fundamental economic and demographic trends.
- Traditionally, innovative medicine growth has occurred most in the years immediately following launch, whereas recent years and the forecast outlook show growth driven by older products.
- North America held the largest share of the global generic drugs market in 2024 and is predicted to maintain the same dominating position throughout the forecast period.
- Unlike liquid formulations, semi-solid ophthalmic drugs offer the advantage of prolonged corneal residence time, leading to sustained drug release and improved therapeutic outcomes.
However,the number of prescriptions for the highest priced drugsdecreased from 13.2 million in 2017 to 11.4 millionin 2022, a 14 percent decrease. This means that spending perprescription among the highest priced drugs increased by 45 percent$6,561 in 2017 to $9,505 in 2022. Table 3 showsdrug expenditures and the total number of prescriptions for specialtydrugs from 2017 to 2022 and also breaks out these statistics for smallmolecule drugs and biological products. Total inflation-adjustedexpenditures on specialty drugs grew from $226 billion in 2017 to $316billion in 2022, a 39.9 percent increase. However, the number ofspecialty prescriptions decreased from 1.16 billion in2017 to 1.09 billion in 2022, a 6.2 percent decrease. This means thatspending per specialty prescription increased 49.2 percent between 2017and 2022, from $195 in 2017 to $291 in 2022.
Unliketheir branded counterparts, pure generics do not carry any brand name and canbe sold at a significantly subsidized rate. This makes them preferable incountries with underserved healthcare infrastructure and among low-incomepatients. Governments also provide significant subsidies for the production ofthese therapeutics, and insurance providers often prioritize pure generics tokeep premiums competitive. These are an exactcopy of branded drugs with the same dosage, active ingredients, andeffectiveness, making them a cost-effective option for patients and healthcareproviders in emerging economies, especially in Asia.
The COVID-19 pandemic has had a significant impact on the pharmacy market, with an increased demand for medications, vaccines, and other healthcare products. Pharmacies have played a critical role in the distribution of COVID-19 vaccines, and have also seen an increase in demand for telehealth services. In response to the pandemic, major pharmacy chains like Walmart, Walgreens Boots Alliance, CVS Health and Rite Aid have reported a sharp increase in demand for flu shots in their U.S. pharmacies in 2020, in some cases double from the previous year. The increasing prevalence of cardiovascular diseases, cancer, diabetes, and neurological disorders is fueling the demand for innovative treatments and personalized medicine. Companies also invest in artificial intelligence (AI), big data analytics, and real-world evidence (RWE) research to enhance drug discovery and market access.
